ASCO Annual Meeting | Conference

COSMIC-021 Data Affirm Activity of Cabozantinib/Atezolizumab in mCRPC

June 8th 2020

Neeraj Agarwal, MD, discusses the COSMIC-021 trial, the findings from cohort 6 in metastatic castration-resistant prostate cancer, and the planned phase 3 trial that will evaluate the combination on a larger scale.

Dr. Rodriguez-Abreu on Updated Results From the KEYNOTE-189 Trial in NSCLC

June 5th 2020

Delvys Rodriguez-Abreu, MD, discusses findings from the final analysis of the phase 3 KEYNOTE-189 study in metastatic nonsquamous non–small cell lung cancer.

Dr. Mascarenhas on the Impact of Ruxolitinib on the Myelofibrosis Treatment Paradigm

June 5th 2020

John O. Mascarenhas, MD, discusses the impact of ruxolitinib in the myelofibrosis treatment paradigm.

Dr. Gwin on the Mechanism of Action of Alpha-TEA in HER2-Positive Metastatic Breast Cancer

June 5th 2020

William R. Gwin III, MD, discusses the mechanism of action of alpha-tocopheryloxyacetic acid in HER2-positive metastatic breast cancer.

Dr. Wolf on Updated Findings With Capmatinib in METex14-Mutant NSCLC

June 4th 2020

Jüergen Wolf, MD, discusses data the phase 2 GEOMETRY mono-1 trial with capmatinib (Tabrecta) in patients with METex14-mutated or high MET amplified advanced non–small cell lung cancer.

Pevonedistat/Azacitidine Shows Favorable Activity in Higher-Risk MDS/CMML, Low-Blast AML

June 3rd 2020

The combination of pevonedistat and azacitidine led to a trend toward improved event-free survival and a numerical improvement in overall survival versus azacitidine alone in patients with higher-risk myelodysplastic syndrome/chronic myelomonocytic leukemia, and low-blast acute myelogenous leukemia.

Dr. Zakashansky on the Benefit of Maintenance Olaparib in BRCA+ Ovarian Cancer

June 3rd 2020

Konstantin Zakashansky, MD, discusses final overall survival data from the phase 3 SOLO2 trial evaluating maintenance olaparib (Lynparza) in platinum-sensitive, relapsed ovarian cancer with a BRCA mutation.

CD71-Directed Probody-Drug Conjugate Shows Safety, Signals of Activity in Advanced Solid Tumors

June 2nd 2020

The CD71-directed probody-drug conjugate of monomethyl auristatin E CX-2029 showed tolerability and antitumor activity in patients with advanced cancer.

Addition of Veliparib to Cisplatin Significantly Improves PFS in BRCA-Like Advanced TNBC

June 2nd 2020

The addition of veliparib to cisplatin resulted in a significant improvement in progression-free survival and a trend toward improved overall survival in patients with BRCA-like triple-negative breast cancer.

Dr. Poveda on the Results of the SOLO2 Trial in Ovarian Cancer

June 2nd 2020

Andres Poveda, MD, discusses the results of the phase 3 SOLO2 trial in advanced ovarian cancer.

x